Exclusive ENT License Rights Sample Clauses

Exclusive ENT License Rights. In addition to the above rights and licenses, if ArthroCare is able to, ArthroCare will offer the "Exclusive ENT License Rights" to Collagen. In such event, Collagen will accept such rights * If ArthroCare offers and Collagen accepts the Exclusive ENT License Rights, Collagen will have, in combination with the rights granted in section 2, an exclusive, non-transferable, worldwide license under the Patent Rights and the Trademark Rights, with the right to use, market, sell and distribute Licensed Products to all physicians in the Field and the ENT Field. In addition, if ArthroCare offers and Collagen accepts the Exclusive ENT License Rights, Collagen's minimum annual royalty payments for Disposable Wands and minimum purchase requirements for the Licensed Products will be increased pursuant to sections 5.3(b) and 7.5(b), respectively.
AutoNDA by SimpleDocs
Exclusive ENT License Rights. In addition to the above rights and licenses, if ArthroCare is able to, ArthroCare will offer the “Exclusive ENT License Rights” to Collagen. In such event, Collagen will accept such rights and pay an additional ENT License Fee of $1million to ArthroCare. This requirement for Collagen to accept such rights will expire on March 31, 1999. If ArthroCare is able to offer the Exclusive ENT License Rights to Collagen after March 31, 1999 and before March 31, 2001, then Collagen shall have the option to accept the Exclusive ENT License Rights for a period of thirty (30) days after the date ArthroCare offers the Exclusive ENT License Rights to Collagen. If Collagen exercises this option, Collagen will pay an additional ENT License Fee of $1 million to ArthroCare. If Collagen does not exercise this option thirty (30) days after the date ArthroCare offers the Exclusive ENT License Rights to Collagen, this option shall expire and Collagen will no longer have any rights under sections 4.1 and 4.2, including the right of first offer described in each of these sections. If ArthroCare is unable to offer the Exclusive ENT License Rights to Collagen by March 31, 2001, this option will expire. During the Term of this Agreement, if ArthroCare is able to offer such Exclusive ENT License Rights to Collagen after March 31, 2001, ArthroCare shall notify Collagen and shall allow Collagen to make the first offer to purchase such rights (right of first offer). If the parties do not mutually agree on the consideration Collagen shall pay ArthroCare for the Exclusive ENT License Rights within thirty (30) days of this notification, ArthroCare shall have the right to offer the Exclusive ENT License Rights to third parties. If ArthroCare offers the Exclusive ENT License Rights to Collagen by March 31, 1999, the first $500,000 of the ENT License Fee will be paid at the later of the signing of a definitive agreement or the time at which ArthroCare offers such rights. The second $500,000 of the ENT License Fee will be paid upon Collagen’s placement of 60 Controllers into accounts that would involve use of the Controller by an ENT physician. If ArthroCare offers the Exclusive ENT License Rights to Collagen after March 31, 1999 and before March 31, 2001, and Collagen exercises its option for these rights as described above, then Collagen shall pay the entire $1 million of the ENT License Fee at the time Collagen exercises its option. If ArthroCare offers and Collagen accepts the Exclusive ENT...
Exclusive ENT License Rights. In addition to the above rights and licenses, if If ArthroCare offers and Collagen accepts the Exclusive ENT License Rights, Collagen will have, in combination with the rights granted in section 2, an exclusive, non-transferable, worldwide license under the Patent Rights and the Trademark Rights, with the right to use, market, sell and distribute Licensed Products to all physicians in the Field and the ENT Field. In addition, if ArthroCare offers and Collagen accepts the Exclusive ENT License Rights, Collagen's minimum annual royalty payments for Disposable Wands and minimum purchase requirements for the Licensed Products will be increased pursuant to sections 5.3(b) and 7.5(b), respectively.

Related to Exclusive ENT License Rights

  • License Rights The rights granted herein in favor of each Service Recipient are in the nature of a license and shall not create any leasehold or other estate or possessory rights in Shared Real Property, and if the license granted under this Article III expires or is terminated, the Service Recipient shall vacate the Shared Real Property, and any occupancy or activity of the Service Recipient thereafter in the Shared Real Property shall be considered a trespass.

  • Patent License Licensor hereby grants to Licensee an exclusive, royalty-bearing, non-transferable license under the Licensed Patents to make, offer to sell, sell and export Licensed Products within the Field of Use and subject to the Field of Use Restrictions. This license shall not include the right to grant sublicenses.

  • Sublicense Rights Subject to the terms and conditions of this Agreement, Astellas shall have the right to grant sublicenses of the rights granted to it under Section 3.1.1 and 2.5.3(c) through multiple tiers to its Affiliates, provided that Astellas shall be and remain responsible for performance of all its obligations under this Agreement, and any action by an Affiliate shall be deemed an action by Astellas for which it is responsible. Astellas and its Affiliates may grant sublicenses through multiple tiers to Third Parties (a) whose primary business is contract manufacturing, solely for manufacturing and supplying Licensed Compound or Product to Astellas or any Related Party or (b) to a subcontractor to perform Astellas’s assigned responsibilities under this Agreement or any Research Plan, Development Plan or Co-Promotion Plan. All other sublicenses to be granted by Astellas or any Astellas Affiliate in the Joint Development Territory prior to […***…] will require prior written approval from Ambit, which shall not be unreasonably withheld or delayed, provided that in the event such sublicense is to all of Astellas’s rights in the U.S. or the Joint Development Territory to a Person who is not an Astellas Affiliate such approval shall be at Ambit’s sole discretion. In the case of sublicenses pursuant to the immediately preceding sentence above, Astellas shall provide to Ambit, upon Ambit’ written request, a copy of all executed agreements in which rights granted by Ambit under this Agreement are sublicensed (and Astellas shall have the right to make reasonable redactions prior to providing such agreements(s)). Ambit shall treat all such sublicense agreements as Astellas’s Confidential Information. Astellas or its Affiliates may grant sublicenses (i) in the Joint Development Territory at any time after the first NDA Submission in the Joint Development Territory, provided that, with respect to each applicable Product in the U.S., the Required Exercise Date has occurred and Ambit has not exercised the Co-Promotion Option or the Co-Promotion Term has expired or terminated and (ii) outside the Joint Development Territory, in each case ((i) and (ii)) through multiple tiers of Sublicensees without Ambit’s approval. Each sublicense granted by Astellas pursuant to this Section 3.1.2 shall be subject and subordinate to the terms and conditions of this Agreement. Any sublicense granted by Astellas shall impose on the Sublicensee obligations consistent with the terms and conditions of this Agreement, with each Sublicensee being required to comply with the obligations under this Agreement applicable to Sublicensees, and also to comply with the generally-applicable obligations of this Agreement that are appropriate for application to Sublicensees. Astellas shall ensure that all Persons to which it (or its Affiliate) grants sublicenses comply with all applicable terms and conditions of this Agreement, and Astellas shall be responsible for any failure of any such Sublicensee to comply with such terms or conditions, with the further understanding that any action or omission by any such Sublicensee that, if committed by Astellas would be a breach of this Agreement (with respect to those country(ies)) in which such Sublicensee is sublicensed), will be deemed a breach by Astellas of this Agreement (with respect to those country(ies) in which such Sublicensee is sublicensed) for which Astellas is responsible. Without limiting the foregoing, no sublicense shall modify Ambit’s rights or obligations under this Agreement (including Ambit’s Co-Promotion rights). Without limiting the foregoing, any sublicense agreement shall contain the following provisions, as applicable: (i) a requirement that such Sublicensee submit applicable Net Sales or other reports consistent with those required hereunder; (ii) audit requirements similar to those set forth in this Agreement; and (iii) a requirement that such Sublicensee comply with the confidentiality provisions of Article 6 with respect to Ambit’s Confidential Information.

  • Patent Licenses (a) Upon payment of the applicable fees as set forth in Appendix B3 and subject to the provisions of this Agreement, Lucent hereby grants to Company during the License Term, a personal, non-transferable (except as permitted in Section 5.08) and non-exclusive license (without any right to sublicense) under (a) patents and/or patent applications listed in Appendix C, (b) patents on sole inventions (as defined in Section 2.03(a) owned by Lucent, to (i) perform the Development Project during the Development Period, and (ii) to make, have made, use, lease, sell, offer to sell and import Licensed Product.

  • Trademark License (a) Reuters and TSI acknowledge that Reuters has, pursuant to the Existing License Agreement, assigned to TSI all of its (and TFT’s) right, title and interest in and to the Transferred TIB-Related Marks and all goodwill associated therewith. Reuters hereby continues to assign to TSI any right, title and interest that it may have or obtain in the Transferred TIB-Related Marks or the goodwill associated therewith. At TSI’s sole expense, Reuters shall perform such acts and execute such documents as are reasonably required to perfect the foregoing assignment and obtain and enforce trademark, service xxxx and other similar rights in the Transferred TIB-Related Marks. TSI hereby grants to Reuters a perpetual, royalty-free, irrevocable, worldwide right and license in favor of Reuters and its Affiliates to use Transferred TIB-Related Marks in connection with the marketing, use, sale and distribution of any of Reuters’ and their Affiliates’ respective products or the provision by Reuters or their Affiliates of any services. Reuters and its Affiliates’ right to use such Transferred TIB-Related Marks shall be only in conformance with TSI’s trademark usage guidelines delivered to Reuters from time to time, which guidelines shall be reasonable and shall not be inconsistent with the scope of the license herein granted and shall not become effective prior to thirty (30) days after notice thereof has been given by TSI. TSI shall maintain the right to substitute any alternative trademark to the Transferred TIB-Related Marks in the event such Transferred TIB-Related Xxxx is held to infringe any other xxxx; provided that, if TSI advises either or both of Reuters in writing of an alleged infringement, Reuters will be responsible for any and all losses, liabilities, damages, costs and expenses assessed or incurred as a result of such actual or alleged infringement that accrue on or after the date of such notice.

  • Development License A non-transferable (except as provided in Section 17.1 (Assignment)), sublicensable (subject to Section 11.2.5 (Voyager Sublicense Rights)), worldwide, non-exclusive, royalty-free license under the Genzyme Technology, Genzyme Collaboration Technology and Genzyme’s interest in the Joint Collaboration Technology to (a) Develop the Split Territory Licensed Products and conduct such Split Territory Licensed Program inside and outside the Voyager Territory for Commercialization of such Split Territory Agreement Products in the Field in the Voyager Territory, and (b) Manufacture the Split Territory Licensed Products inside or outside of the Voyager Territory for the purposes of such Development, in each case (a) and (b) as and to the extent set forth in any Global Development Plan or Voyager Territory Development Plan.

  • PATENT LICENSE AGREEMENT EXCLUSIVE PHS and Licensee agree as follows:

  • Trademark License Agreement Buyer shall have executed and delivered to Sellers the Trademark License Agreement.

  • Trademark Licenses The parties hereby grant to each other non-exclusive, fully-paid, royalty-free licenses to utilize the other party’s trademarks, as follows:

  • Exclusive License Licensor hereby grants to Licensee and Licensee hereby accepts from Licensor, upon the terms and conditions herein specified, a sole and exclusive license under the Licensed Patent Rights in the Territory, and in the Field of Use to develop, make, have made, import, have imported, use, offer to sell, sell and otherwise commercialize Licensed Product(s).

Time is Money Join Law Insider Premium to draft better contracts faster.